Literature DB >> 17250658

HRAS and the Costello syndrome.

K A Rauen1.   

Abstract

Costello syndrome (CS) is a complex developmental disorder involving characteristic craniofacial features, failure to thrive, developmental delay, cardiac and skeletal anomalies and a predisposition to develop neoplasia, both benign and malignant. CS is caused by activating germline mutations in HRAS and belongs to an exciting class of genetic syndromes that are caused by perturbation of function through the Ras pathway. Some of these other syndromes include Noonan syndrome, LEOPARD syndrome, neurofibromatosis 1 and cardio-facio-cutaneous syndrome. Ras is a critical signaling hub in the cell and is activated by receptor tyrosine kinases, G-protein-coupled receptors, cytokine receptors and extracellular matrix receptors. The downstream effectors of Ras are many and control vital cellular functions including cell cycle progression, cell survival, motility, transcription, translation and membrane trafficking. Understanding the genetic etiology of CS is the first step in gaining insight to the role Ras plays in human development, cellular signaling and cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250658     DOI: 10.1111/j.1399-0004.2007.00743.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  39 in total

Review 1.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

2.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

3.  C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.

Authors:  Michael Klüppel; Payman Samavarchi-Tehrani; Kela Liu; Jeffrey L Wrana; Aleksander Hinek
Journal:  Eur J Hum Genet       Date:  2012-02-08       Impact factor: 4.246

4.  Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells.

Authors:  Cristina Santoriello; Gianluca Deflorian; Federica Pezzimenti; Koichi Kawakami; Luisa Lanfrancone; Fabrizio d'Adda di Fagagna; Marina Mione
Journal:  Dis Model Mech       Date:  2008-12-22       Impact factor: 5.758

5.  Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.

Authors:  Sanjana Sen; Severa Bunda; Junyan Shi; Andrew Wang; Thomas F Mitts; Aleksander Hinek
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

6.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

7.  Intellectual disability, oncogenes and tumour suppressor genes: the way forward?

Authors:  M Bidart; C Coutton
Journal:  J Genet       Date:  2012-08       Impact factor: 1.166

Review 8.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

Review 9.  MAP'ing CNS development and cognition: an ERKsome process.

Authors:  Ivy S Samuels; Sulagna C Saitta; Gary E Landreth
Journal:  Neuron       Date:  2009-01-29       Impact factor: 17.173

10.  Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling.

Authors:  Haley E Titus; Alejandro López-Juárez; Sadiq H Silbak; Tilat A Rizvi; Madeleine Bogard; Nancy Ratner
Journal:  Glia       Date:  2017-08-30       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.